<antigenSupportingData>
<immunity>
</immunity>
<contraindications>
<vaccineGroup>
<contraindication>
<observationCode>122</observationCode>
<observationTitle>Severe allergic reaction after previous dose of COVID-19</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had a severe allergic reaction after a previous dose of COVID-19 vaccine.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
<contraindication>
<observationCode>080</observationCode>
<observationTitle>Adverse reaction to vaccine component</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an adverse reaction to a vaccine component.</contraindicationText>
<contraindicationGuidance/>
<beginAge/>
<endAge/>
</contraindication>
</vaccineGroup>
<vaccine>
<contraindication>
<observationCode>187</observationCode>
<observationTitle>Allergic reaction to polysorbate 80</observationTitle>
<contraindicationText>Do not vaccinate if the patient has had an immediate allergic reaction of any severity to polysorbate 80.</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
<contraindication>
<observationCode>188</observationCode>
<observationTitle>Known allergy to Polyethylene glycol [PEG]</observationTitle>
<contraindicationText>Do not vaccinate if the patient has known allergy to Polyethylene glycol [PEG].</contraindicationText>
<contraindicationGuidance/>
<contraindicatedVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
<contraindicatedVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
<contraindicatedVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge/>
<endAge/>
</contraindicatedVaccine>
</contraindication>
</vaccine>
</contraindications>
<series>
<seriesName>2-dose 5-17 Pfizer Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>Yes</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart>18 years</maxAgeToStart>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>5 years</minAge>
<earliestRecAge>5 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>5 years</beginAge>
<endAge>12 years</endAge>
<tradeName/>
<mvx/>
<volume>0.2</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>5 years</minAge>
<earliestRecAge>5 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>5 years</beginAge>
<endAge>12 years</endAge>
<tradeName/>
<mvx/>
<volume>0.2</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>65 years</minAge>
<earliestRecAge>65 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>3-dose Pfizer series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>18 years</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>18 years</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>65 years</minAge>
<earliestRecAge>65 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>3-dose Moderna series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>65 years</minAge>
<earliestRecAge>65 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose Janssen series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>Because the efficacy of the Janssen vaccine in people aged less than 18 years has not been established, a single dose of the Pfizer-BioNTech COVID-19 Vaccine could be considered at least 2 months after the Janssen COVID-19 Vaccine.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>4</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 208; 210; 211; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>8 weeks - 4 days</absMinInt>
<minInt>8 weeks</minInt>
<earliestRecInt>8 weeks</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>3-dose mRNA series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>If Moderna vaccine administered as the first dose before 18 years, it is suggested to give Pfizer-BioNTech vaccine as the second dose (at least 28 days after the Moderna vaccine dose) because Pfizer-BioNTech is authorized in this age group.</seriesAdminGuidance>
<seriesType>Standard</seriesType>
<equivalentSeriesGroups>2; 3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>Standard</seriesGroupName>
<seriesGroup>1</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>5</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>5 years</minAge>
<earliestRecAge>5 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>5 years</beginAge>
<endAge>12 years</endAge>
<tradeName/>
<mvx/>
<volume>0.2</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>5 years</minAge>
<earliestRecAge>5 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>5 years</beginAge>
<endAge>12 years</endAge>
<tradeName/>
<mvx/>
<volume>0.2</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>65 years</minAge>
<earliestRecAge>65 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 4-dose Immunocompromised Pfizer series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>Yes</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 4</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 4-dose Immunocompromised Moderna series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 4</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 2-dose Immunocompromised Janssen series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>Because the efficacy of the Janssen vaccine in people aged less than 18 years has not been established, a single dose of the Pfizer-BioNTech COVID-19 Vaccine could be considered at least 2 months after the Janssen COVID-19 Vaccine.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 208; 210; 211; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>8 weeks - 4 days</absMinInt>
<minInt>8 weeks</minInt>
<earliestRecInt>8 weeks</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 4-dose Immunocompromised mRNA series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>A patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.</seriesAdminGuidance>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>If Moderna vaccine administered as the first dose before 18 years, it is suggested to give Pfizer-BioNTech vaccine as the second dose (at least 28 days after the Moderna vaccine dose) because Pfizer-BioNTech is authorized in this age group.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>4</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Recipient of a hematopoietic stem cell transplant</text>
<code>004</code>
</observationCode>
<description>Administer to recipients of a hematopoietic stem cell transplant [HSCT] within 2 years of successful transplantation.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Severe antibody deficiencies</text>
<code>145</code>
</observationCode>
<description>Administer to persons who have severe B-lymphocyte (humoral) - antibody deficiencies (e.g., X-linked agammaglobulinemia and common variable immunodeficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Complete defects</text>
<code>147</code>
</observationCode>
<description>Administer to persons who have complete cell-mediated or humoral T-lymphocyte defects (e.g., severe combined immunodeficiency [SCID] disease, complete DiGeorge syndrome).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>T-lymphocyte [cell-mediated and humoral] - Partial defects</text>
<code>148</code>
</observationCode>
<description>Administer to persons who have partial cell-mediated or humoral T-lymphocyte defects (e.g., most patients with DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Phagocytic function - Leukocyte adhesion defect, and myeloperoxidase deficiency</text>
<code>153</code>
</observationCode>
<description>Administer to persons who have a phagocytic function defect (e.g. leukocyte adhesion defect and myeloperoxidase deficiency).</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - Severely immunocompromised</text>
<code>154</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Transplantation</text>
<code>157</code>
</observationCode>
<description>Administer to persons who have received a transplant.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Immunosuppressive therapy</text>
<code>158</code>
</observationCode>
<description>Administer to persons who are undergoing immunosuppressive therapy. Immunosuppressive medications include those given to prevent solid organ transplant rejection, human immune mediators like interleukins and colony-stimulating factors, immune modulators like levamisol and BCG bladder-tumor therapy, and medicines like tumor necrosis factor alpha inhibitors and anti-B cell antibodies. </description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Radiation therapy</text>
<code>159</code>
</observationCode>
<description>Administer to persons who are undergoing radiation therapy.</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance>When immunocompromising therapy is being planned, vaccination should be completed at least 2 weeks before initiation or resumption of therapy.</guidance>
</indication>
<indication>
<observationCode>
<text>Active treatement for solid tumors</text>
<code>189</code>
</observationCode>
<description>Administer to persons receiving active treatement for solid tumors</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Active treatement for hematologic malignancies</text>
<code>190</code>
</observationCode>
<description>Administer to persons receiving active treatement for hematologic malignancies</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<indication>
<observationCode>
<text>Receipt of CAR-T-cell therapy</text>
<code>191</code>
</observationCode>
<description>Adminster to persons receiving CAR-T-cell therapy</description>
<beginAge>12 years</beginAge>
<endAge/>
<guidance/>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge/>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge/>
<minAge>12 years</minAge>
<earliestRecAge>12 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 4</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose Increased Risk Pfizer series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>B</seriesPriority>
<seriesPreference>5</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Pregnancy</text>
<code>007</code>
</observationCode>
<description>Administer to persons who are pregnant.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Diabetes</text>
<code>014</code>
</observationCode>
<description>Administer to persons who have diabetes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic liver disease</text>
<code>015</code>
</observationCode>
<description>Administer to persons who have chronic liver disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic heart disease</text>
<code>016</code>
</observationCode>
<description>Administer to persons who have chronic heart disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes heart failure, coronary artery disease, etc.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic lung disease</text>
<code>017</code>
</observationCode>
<description>Administer to persons who have chronic lung disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes COPD</guidance>
</indication>
<indication>
<observationCode>
<text>Asthma</text>
<code>027</code>
</observationCode>
<description>Administer to persons who have asthma.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years with moderate-to-severe asthma should receive a booster shot. Persons aged 18-49 years with moderate-to-severe asthma may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Tuberculosis</text>
<code>031</code>
</observationCode>
<description>Administer to persons who have tuberculosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Smoke Cigarettes</text>
<code>042</code>
</observationCode>
<description>Administer to persons who smoke cigarettes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years who smoke cigarettes (current or former) should receive a booster shot. Persons aged 18-49 years smoke cigarettes (current or former) may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Less severe antibody deficiencies</text>
<code>146</code>
</observationCode>
<description>Administer to persons who have less severe B-lymphocyte [humoral] - antibody deficiencies [e.g., selective IgA deficiency and IgG subclass deficiency].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Persistent complement, properdin, or factor B deficiency</text>
<code>151</code>
</observationCode>
<description>Administer to persons who have persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab [Soliris].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - not severely immunocompromised</text>
<code>155</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are not severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Anatomical or functional asplenia</text>
<code>160</code>
</observationCode>
<description>Administer to persons with anatomic or functional asplenia, including sickle cell disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic renal disease</text>
<code>161</code>
</observationCode>
<description>Administer to persons who have chronic renal disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Occupations at increased risk for COVID-19 exposure and transmission</text>
<code>195</code>
</observationCode>
<description>Administer to persons with occupations at increased risk for COVID-19 exposure and transmission.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Occupations at increased risk for COVID-19 exposure and transmission and may get a booster shot based on their individual benefits and risks. Occupatoins at increased risk can be found online at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html#HighRisk</guidance>
</indication>
<indication>
<observationCode>
<text>Residing in an institutional setting at increased risk for COVID-19 exposure and transmission</text>
<code>196</code>
</observationCode>
<description>Administer to persons residing in an institutional setting at increased risk for COVID-19 exposure and transmission</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Institutional settings such as health care, schools, correctional facilities, and homeless shelters at increased risk for COVID-19 exposure and transmission and may get a booster shot </guidance>
</indication>
<indication>
<observationCode>
<text>Resident of long term care facility</text>
<code>197</code>
</observationCode>
<description>Administer to persons residing in a long term care facility</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>Persons aged 18 years and older should receive a booster shot.</guidance>
</indication>
<indication>
<observationCode>
<text>Cancer</text>
<code>198</code>
</observationCode>
<description>Administer to persons with cancer</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Interstitial lung disease</text>
<code>199</code>
</observationCode>
<description>Administer to persons with interstitial lung disease</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cystic fibrosis</text>
<code>200</code>
</observationCode>
<description>Administer to persons with cystic fibrosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Pulmonary hypertension</text>
<code>201</code>
</observationCode>
<description>Administer to persons with pulmonary hypertension</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Dementia</text>
<code>202</code>
</observationCode>
<description>Administer to persons with dementia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Down syndrome</text>
<code>203</code>
</observationCode>
<description>Administer to persons with down syndrome</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Obesity</text>
<code>204</code>
</observationCode>
<description>Administer to persons with obesity</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes BMI calculations of overweight, obese, or severely obese</guidance>
</indication>
<indication>
<observationCode>
<text>Thalassemia</text>
<code>205</code>
</observationCode>
<description>Administer to persons with thalassemia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cerebrovascular disease</text>
<code>206</code>
</observationCode>
<description>Administer to persons with cerebrovascular disease such as having a stroke</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Substance use disorder</text>
<code>207</code>
</observationCode>
<description>Administer to persons with substance use disorders (e.g., alcohol, opiod, cocaine)</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Mental health conditions</text>
<code>208</code>
</observationCode>
<description>Administer to persons with mental health conditions</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes mood disorders, depression, and schizophrenia spectrum disorders.</guidance>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>21 days - 4 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose Increased Risk Moderna series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>B</seriesPriority>
<seriesPreference>6</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Pregnancy</text>
<code>007</code>
</observationCode>
<description>Administer to persons who are pregnant.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Diabetes</text>
<code>014</code>
</observationCode>
<description>Administer to persons who have diabetes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic liver disease</text>
<code>015</code>
</observationCode>
<description>Administer to persons who have chronic liver disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic heart disease</text>
<code>016</code>
</observationCode>
<description>Administer to persons who have chronic heart disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes heart failure, coronary artery disease, etc.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic lung disease</text>
<code>017</code>
</observationCode>
<description>Administer to persons who have chronic lung disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes COPD</guidance>
</indication>
<indication>
<observationCode>
<text>Asthma</text>
<code>027</code>
</observationCode>
<description>Administer to persons who have asthma.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years with moderate-to-severe asthma should receive a booster shot. Persons aged 18-49 years with moderate-to-severe asthma may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Tuberculosis</text>
<code>031</code>
</observationCode>
<description>Administer to persons who have tuberculosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Smoke Cigarettes</text>
<code>042</code>
</observationCode>
<description>Administer to persons who smoke cigarettes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years who smoke cigarettes (current or former) should receive a booster shot. Persons aged 18-49 years smoke cigarettes (current or former) may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Less severe antibody deficiencies</text>
<code>146</code>
</observationCode>
<description>Administer to persons who have less severe B-lymphocyte [humoral] - antibody deficiencies [e.g., selective IgA deficiency and IgG subclass deficiency].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Persistent complement, properdin, or factor B deficiency</text>
<code>151</code>
</observationCode>
<description>Administer to persons who have persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab [Soliris].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - not severely immunocompromised</text>
<code>155</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are not severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Anatomical or functional asplenia</text>
<code>160</code>
</observationCode>
<description>Administer to persons with anatomic or functional asplenia, including sickle cell disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic renal disease</text>
<code>161</code>
</observationCode>
<description>Administer to persons who have chronic renal disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Occupations at increased risk for COVID-19 exposure and transmission</text>
<code>195</code>
</observationCode>
<description>Administer to persons with occupations at increased risk for COVID-19 exposure and transmission.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Occupations at increased risk for COVID-19 exposure and transmission and may get a booster shot based on their individual benefits and risks. Occupatoins at increased risk can be found online at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html#HighRisk</guidance>
</indication>
<indication>
<observationCode>
<text>Residing in an institutional setting at increased risk for COVID-19 exposure and transmission</text>
<code>196</code>
</observationCode>
<description>Administer to persons residing in an institutional setting at increased risk for COVID-19 exposure and transmission</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Institutional settings such as health care, schools, correctional facilities, and homeless shelters at increased risk for COVID-19 exposure and transmission and may get a booster shot </guidance>
</indication>
<indication>
<observationCode>
<text>Resident of long term care facility</text>
<code>197</code>
</observationCode>
<description>Administer to persons residing in a long term care facility</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>Persons aged 18 years and older should receive a booster shot.</guidance>
</indication>
<indication>
<observationCode>
<text>Cancer</text>
<code>198</code>
</observationCode>
<description>Administer to persons with cancer</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Interstitial lung disease</text>
<code>199</code>
</observationCode>
<description>Administer to persons with interstitial lung disease</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cystic fibrosis</text>
<code>200</code>
</observationCode>
<description>Administer to persons with cystic fibrosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Pulmonary hypertension</text>
<code>201</code>
</observationCode>
<description>Administer to persons with pulmonary hypertension</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Dementia</text>
<code>202</code>
</observationCode>
<description>Administer to persons with dementia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Down syndrome</text>
<code>203</code>
</observationCode>
<description>Administer to persons with down syndrome</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Obesity</text>
<code>204</code>
</observationCode>
<description>Administer to persons with obesity</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes BMI calculations of overweight, obese, or severely obese</guidance>
</indication>
<indication>
<observationCode>
<text>Thalassemia</text>
<code>205</code>
</observationCode>
<description>Administer to persons with thalassemia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cerebrovascular disease</text>
<code>206</code>
</observationCode>
<description>Administer to persons with cerebrovascular disease such as having a stroke</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Substance use disorder</text>
<code>207</code>
</observationCode>
<description>Administer to persons with substance use disorders (e.g., alcohol, opiod, cocaine)</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Mental health conditions</text>
<code>208</code>
</observationCode>
<description>Administer to persons with mental health conditions</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes mood disorders, depression, and schizophrenia spectrum disorders.</guidance>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>Y</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>18 years - 4 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>208; 210; 211; 212; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 2-dose Increased Risk Janssen series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>Because the efficacy of the Janssen vaccine in people aged less than 18 years has not been established, a single dose of the Pfizer-BioNTech COVID-19 Vaccine could be considered at least 2 months after the Janssen COVID-19 Vaccine.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>B</seriesPriority>
<seriesPreference>7</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Pregnancy</text>
<code>007</code>
</observationCode>
<description>Administer to persons who are pregnant.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Diabetes</text>
<code>014</code>
</observationCode>
<description>Administer to persons who have diabetes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic liver disease</text>
<code>015</code>
</observationCode>
<description>Administer to persons who have chronic liver disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic heart disease</text>
<code>016</code>
</observationCode>
<description>Administer to persons who have chronic heart disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes heart failure, coronary artery disease, etc.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic lung disease</text>
<code>017</code>
</observationCode>
<description>Administer to persons who have chronic lung disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes COPD</guidance>
</indication>
<indication>
<observationCode>
<text>Asthma</text>
<code>027</code>
</observationCode>
<description>Administer to persons who have asthma.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years with moderate-to-severe asthma should receive a booster shot. Persons aged 18-49 years with moderate-to-severe asthma may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Tuberculosis</text>
<code>031</code>
</observationCode>
<description>Administer to persons who have tuberculosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Smoke Cigarettes</text>
<code>042</code>
</observationCode>
<description>Administer to persons who smoke cigarettes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years who smoke cigarettes (current or former) should receive a booster shot. Persons aged 18-49 years smoke cigarettes (current or former) may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Less severe antibody deficiencies</text>
<code>146</code>
</observationCode>
<description>Administer to persons who have less severe B-lymphocyte [humoral] - antibody deficiencies [e.g., selective IgA deficiency and IgG subclass deficiency].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Persistent complement, properdin, or factor B deficiency</text>
<code>151</code>
</observationCode>
<description>Administer to persons who have persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab [Soliris].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - not severely immunocompromised</text>
<code>155</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are not severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Anatomical or functional asplenia</text>
<code>160</code>
</observationCode>
<description>Administer to persons with anatomic or functional asplenia, including sickle cell disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic renal disease</text>
<code>161</code>
</observationCode>
<description>Administer to persons who have chronic renal disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Occupations at increased risk for COVID-19 exposure and transmission</text>
<code>195</code>
</observationCode>
<description>Administer to persons with occupations at increased risk for COVID-19 exposure and transmission.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Occupations at increased risk for COVID-19 exposure and transmission and may get a booster shot based on their individual benefits and risks. Occupatoins at increased risk can be found online at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html#HighRisk</guidance>
</indication>
<indication>
<observationCode>
<text>Residing in an institutional setting at increased risk for COVID-19 exposure and transmission</text>
<code>196</code>
</observationCode>
<description>Administer to persons residing in an institutional setting at increased risk for COVID-19 exposure and transmission</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Institutional settings such as health care, schools, correctional facilities, and homeless shelters at increased risk for COVID-19 exposure and transmission and may get a booster shot </guidance>
</indication>
<indication>
<observationCode>
<text>Resident of long term care facility</text>
<code>197</code>
</observationCode>
<description>Administer to persons residing in a long term care facility</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>Persons aged 18 years and older should receive a booster shot.</guidance>
</indication>
<indication>
<observationCode>
<text>Cancer</text>
<code>198</code>
</observationCode>
<description>Administer to persons with cancer</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Interstitial lung disease</text>
<code>199</code>
</observationCode>
<description>Administer to persons with interstitial lung disease</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cystic fibrosis</text>
<code>200</code>
</observationCode>
<description>Administer to persons with cystic fibrosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Pulmonary hypertension</text>
<code>201</code>
</observationCode>
<description>Administer to persons with pulmonary hypertension</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Dementia</text>
<code>202</code>
</observationCode>
<description>Administer to persons with dementia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Down syndrome</text>
<code>203</code>
</observationCode>
<description>Administer to persons with down syndrome</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Obesity</text>
<code>204</code>
</observationCode>
<description>Administer to persons with obesity</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes BMI calculations of overweight, obese, or severely obese</guidance>
</indication>
<indication>
<observationCode>
<text>Thalassemia</text>
<code>205</code>
</observationCode>
<description>Administer to persons with thalassemia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cerebrovascular disease</text>
<code>206</code>
</observationCode>
<description>Administer to persons with cerebrovascular disease such as having a stroke</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Substance use disorder</text>
<code>207</code>
</observationCode>
<description>Administer to persons with substance use disorders (e.g., alcohol, opiod, cocaine)</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Mental health conditions</text>
<code>208</code>
</observationCode>
<description>Administer to persons with mental health conditions</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes mood disorders, depression, and schizophrenia spectrum disorders.</guidance>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>207; 208; 210; 211; 213</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>8 weeks - 4 days</absMinInt>
<minInt>8 weeks</minInt>
<earliestRecInt>8 weeks</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>Risk 3-dose Increased Risk mRNA series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance>COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity of COVID-19 vaccine is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines or live vaccines. When deciding whether to coadminister another vaccine(s) with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Vaccination should be deferred until recovery from acute illness (if person had symptoms) and criteria have been met to discontinue isolation.</seriesAdminGuidance>
<seriesAdminGuidance>Given the lack of data on the safety of COVID-19 vaccines in people with a history of MIS-C or MIS-A, a conversation between the patient, their guardian(s), and their clinical team or a specialist is strongly encouraged to assist with decisions about the use of COVID-19 vaccines.</seriesAdminGuidance>
<seriesAdminGuidance>Currently no data on safety or efficacy of COVID-19 vaccination in persons who received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. Vaccination should be deferred for at least 90 days to avoid interference of the treatment with vaccine-induced immune responses.</seriesAdminGuidance>
<seriesAdminGuidance>If Moderna vaccine administered as the first dose before 18 years, it is suggested to give Pfizer-BioNTech vaccine as the second dose (at least 28 days after the Moderna vaccine dose) because Pfizer-BioNTech is authorized in this age group.</seriesAdminGuidance>
<seriesType>Risk</seriesType>
<equivalentSeriesGroups>3</equivalentSeriesGroups>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>Yes</productPath>
<seriesGroupName>Increased Risk</seriesGroupName>
<seriesGroup>2</seriesGroup>
<seriesPriority>B</seriesPriority>
<seriesPreference>8</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication>
<observationCode>
<text>Pregnancy</text>
<code>007</code>
</observationCode>
<description>Administer to persons who are pregnant.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Diabetes</text>
<code>014</code>
</observationCode>
<description>Administer to persons who have diabetes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic liver disease</text>
<code>015</code>
</observationCode>
<description>Administer to persons who have chronic liver disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic heart disease</text>
<code>016</code>
</observationCode>
<description>Administer to persons who have chronic heart disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes heart failure, coronary artery disease, etc.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic lung disease</text>
<code>017</code>
</observationCode>
<description>Administer to persons who have chronic lung disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes COPD</guidance>
</indication>
<indication>
<observationCode>
<text>Asthma</text>
<code>027</code>
</observationCode>
<description>Administer to persons who have asthma.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years with moderate-to-severe asthma should receive a booster shot. Persons aged 18-49 years with moderate-to-severe asthma may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Tuberculosis</text>
<code>031</code>
</observationCode>
<description>Administer to persons who have tuberculosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Smoke Cigarettes</text>
<code>042</code>
</observationCode>
<description>Administer to persons who smoke cigarettes.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years who smoke cigarettes (current or former) should receive a booster shot. Persons aged 18-49 years smoke cigarettes (current or former) may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>B-lymphocyte [humoral] - Less severe antibody deficiencies</text>
<code>146</code>
</observationCode>
<description>Administer to persons who have less severe B-lymphocyte [humoral] - antibody deficiencies [e.g., selective IgA deficiency and IgG subclass deficiency].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Persistent complement, properdin, or factor B deficiency</text>
<code>151</code>
</observationCode>
<description>Administer to persons who have persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or who are taking eculizumab [Soliris].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>HIV/AIDS - not severely immunocompromised</text>
<code>155</code>
</observationCode>
<description>Administer to persons who have HIV/AIDS and are not severely immunocompromised [See the CDC general recommendations for a definition of "severely immunocompromised"].</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Anatomical or functional asplenia</text>
<code>160</code>
</observationCode>
<description>Administer to persons with anatomic or functional asplenia, including sickle cell disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Chronic renal disease</text>
<code>161</code>
</observationCode>
<description>Administer to persons who have chronic renal disease.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Occupations at increased risk for COVID-19 exposure and transmission</text>
<code>195</code>
</observationCode>
<description>Administer to persons with occupations at increased risk for COVID-19 exposure and transmission.</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Occupations at increased risk for COVID-19 exposure and transmission and may get a booster shot based on their individual benefits and risks. Occupatoins at increased risk can be found online at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html#HighRisk</guidance>
</indication>
<indication>
<observationCode>
<text>Residing in an institutional setting at increased risk for COVID-19 exposure and transmission</text>
<code>196</code>
</observationCode>
<description>Administer to persons residing in an institutional setting at increased risk for COVID-19 exposure and transmission</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Institutional settings such as health care, schools, correctional facilities, and homeless shelters at increased risk for COVID-19 exposure and transmission and may get a booster shot </guidance>
</indication>
<indication>
<observationCode>
<text>Resident of long term care facility</text>
<code>197</code>
</observationCode>
<description>Administer to persons residing in a long term care facility</description>
<beginAge>18 years</beginAge>
<endAge/>
<guidance>Persons aged 18 years and older should receive a booster shot.</guidance>
</indication>
<indication>
<observationCode>
<text>Cancer</text>
<code>198</code>
</observationCode>
<description>Administer to persons with cancer</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Interstitial lung disease</text>
<code>199</code>
</observationCode>
<description>Administer to persons with interstitial lung disease</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cystic fibrosis</text>
<code>200</code>
</observationCode>
<description>Administer to persons with cystic fibrosis</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Pulmonary hypertension</text>
<code>201</code>
</observationCode>
<description>Administer to persons with pulmonary hypertension</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Dementia</text>
<code>202</code>
</observationCode>
<description>Administer to persons with dementia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Down syndrome</text>
<code>203</code>
</observationCode>
<description>Administer to persons with down syndrome</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Obesity</text>
<code>204</code>
</observationCode>
<description>Administer to persons with obesity</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes BMI calculations of overweight, obese, or severely obese</guidance>
</indication>
<indication>
<observationCode>
<text>Thalassemia</text>
<code>205</code>
</observationCode>
<description>Administer to persons with thalassemia</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Cerebrovascular disease</text>
<code>206</code>
</observationCode>
<description>Administer to persons with cerebrovascular disease such as having a stroke</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Substance use disorder</text>
<code>207</code>
</observationCode>
<description>Administer to persons with substance use disorders (e.g., alcohol, opiod, cocaine)</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks.</guidance>
</indication>
<indication>
<observationCode>
<text>Mental health conditions</text>
<code>208</code>
</observationCode>
<description>Administer to persons with mental health conditions</description>
<beginAge>18 years</beginAge>
<endAge>65 years</endAge>
<guidance>Persons aged 50-64 years should receive a booster shot. Persons aged 18-49 years may receive a booster shot based on their individual benefits and risks. Includes mood disorders, depression, and schizophrenia spectrum disorders.</guidance>
</indication>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge/>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate>20211024</cessationDate>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>28 days - 4 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt>42 days</latestRecInt>
<intervalPriority/>
<effectiveDate>20211025</effectiveDate>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
<beginAge>0 days</beginAge>
<endAge>18 years</endAge>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 3</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>N</fromPrevious>
<fromTargetDose/>
<fromMostRecent>210; 211; 212</fromMostRecent>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>6 months - 4 days</absMinInt>
<minInt>6 months</minInt>
<earliestRecInt>6 months</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.25</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>12 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.3</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<preferableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>18 years</beginAge>
<endAge/>
<tradeName/>
<mvx/>
<volume>0.5</volume>
<forecastVaccineType>N</forecastVaccineType>
</preferableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose</vaccineType>
<cvx>207</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose</vaccineType>
<cvx>208</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL</vaccineType>
<cvx>212</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<allowableVaccine>
<vaccineType>SARS-COV-2 (COVID-19) vaccine, Unspecified Formulation</vaccineType>
<cvx>213</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine>
<vaccineType>COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose</vaccineType>
<cvx>218</cvx>
</inadvertentVaccine>
<conditionalSkip>
<context>Forecast</context>
<setLogic>n/a</setLogic>
<set>
<setID>1</setID>
<setDescription>Target Dose should not be forecasted for anyone under 18 years of age</setDescription>
<effectiveDate/>
<cessationDate/>
<conditionLogic/>
<condition>
<conditionID>1</conditionID>
<conditionType>Age</conditionType>
<startDate/>
<endDate/>
<beginAge/>
<endAge>18 years</endAge>
<interval/>
<doseCount/>
<doseType/>
<doseCountLogic/>
<vaccineTypes/>
<seriesGroups/>
</condition>
</set>
</conditionalSkip>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose AstraZeneca Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized or Clinical Trial Vaccines</seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>1</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL</vaccineType>
<cvx>210</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>8 weeks</minInt>
<earliestRecInt>8 weeks</earliestRecInt>
<latestRecInt>12 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL</vaccineType>
<cvx>210</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose BIBP Sinopharm Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized or Clinical Trial Vaccines</seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>2</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)</vaccineType>
<cvx>510</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>3 weeks</minInt>
<earliestRecInt>3 weeks</earliestRecInt>
<latestRecInt>4 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)</vaccineType>
<cvx>510</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose CoronaVac Sinovac Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized or Clinical Trial Vaccines</seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>3</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)</vaccineType>
<cvx>511</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>2 weeks</minInt>
<earliestRecInt>2 weeks</earliestRecInt>
<latestRecInt>4 weeks</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<absMinInt>0 days</absMinInt>
<effectiveDate/>
<cessationDate/>
</allowableInterval>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)</vaccineType>
<cvx>511</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose Novavax Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized or Clinical Trial Vaccines</seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>4</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>18 years</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL</vaccineType>
<cvx>211</cvx>
<beginAge>18 years</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>18 years</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>21 days</minInt>
<earliestRecInt>21 days</earliestRecInt>
<latestRecInt>28 days</latestRecInt>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL</vaccineType>
<cvx>211</cvx>
<beginAge>18 years</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
<series>
<seriesName>2-dose COVAXIN Series</seriesName>
<targetDisease>COVID-19</targetDisease>
<vaccineGroup>COVID-19</vaccineGroup>
<seriesAdminGuidance/>
<seriesType>Evaluation Only</seriesType>
<equivalentSeriesGroups/>
<requiredGender/>
<selectSeries>
<defaultSeries>No</defaultSeries>
<productPath>No</productPath>
<seriesGroupName>WHO-Authorized or Clinical Trial Vaccines</seriesGroupName>
<seriesGroup>3</seriesGroup>
<seriesPriority>A</seriesPriority>
<seriesPreference>5</seriesPreference>
<minAgeToStart/>
<maxAgeToStart/>
</selectSeries>
<indication/>
<seriesDose>
<doseNumber>Dose 1</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval/>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (COVAXIN)</vaccineType>
<cvx>502</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
<seriesDose>
<doseNumber>Dose 2</doseNumber>
<age>
<absMinAge>0 days</absMinAge>
<minAge>18 years</minAge>
<earliestRecAge>18 years</earliestRecAge>
<latestRecAge/>
<maxAge/>
<effectiveDate/>
<cessationDate/>
</age>
<interval>
<fromPrevious>Y</fromPrevious>
<fromTargetDose/>
<fromMostRecent/>
<fromRelevantObs/>
<absMinInt>0 days</absMinInt>
<minInt>28 days</minInt>
<earliestRecInt>28 days</earliestRecInt>
<latestRecInt/>
<intervalPriority/>
<effectiveDate/>
<cessationDate/>
</interval>
<allowableInterval/>
<preferableVaccine/>
<allowableVaccine>
<vaccineType>COVID-19 IV Non-US Vaccine (COVAXIN)</vaccineType>
<cvx>502</cvx>
<beginAge>0 days</beginAge>
<endAge/>
</allowableVaccine>
<inadvertentVaccine/>
<conditionalSkip/>
<recurringDose>No</recurringDose>
<seasonalRecommendation/>
</seriesDose>
</series>
</antigenSupportingData>
